Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08FWK
|
||||
| Former ID |
DIB005900
|
||||
| Drug Name |
Oxypurinol
|
||||
| Synonyms |
Oxypurinol (intravenous)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Heart failure [ICD9: 428; ICD10:I50] | Phase 2/3 | [1] | ||
| Company |
Johns Hopkins University
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C5H4N4O2
|
||||
| Canonical SMILES |
O=C1NC(=O)c2c[nH]nc2N1
|
||||
| InChI |
1S/C5H4N4O2/c10-4-2-1-6-9-3(2)7-5(11)8-4/h1H,(H3,6,7,8,9,10,11)
|
||||
| InChIKey |
HXNFUBHNUDHIGC-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Xanthine dehydrogenase/oxidase | Target Info | Inhibitor | [2] | |
| BioCyc Pathway | Purine nucleotides degradation | ||||
| Urate biosynthesis/inosine 5'-phosphate degradation | |||||
| Guanosine nucleotides degradation | |||||
| Adenosine nucleotides degradation | |||||
| Retinoate biosynthesis II | |||||
| KEGG Pathway | Purine metabolism | ||||
| Caffeine metabolism | |||||
| Drug metabolism - other enzymes | |||||
| Metabolic pathways | |||||
| Peroxisome | |||||
| PANTHER Pathway | Adenine and hypoxanthine salvage pathway | ||||
| Purine metabolism | |||||
| PathWhiz Pathway | Caffeine Metabolism | ||||
| Purine Metabolism | |||||
| Reactome | Purine catabolism | ||||
| WikiPathways | Oxidative Stress | ||||
| Effects of Nitric Oxide | |||||
| Metabolism of nucleotides | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00063687) Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure. U.S. National Institutes of Health. | ||||
| REF 2 | Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.